GgoogleDE first seen 25 d ago, last 3 d ago, peak #2
BioNTech faces works council complaints and cancer drug setback
Original: biontech
BioNTech is under pressure on two fronts in Germany. The company's works council has publicly criticised toxic working conditions and internal shortcomings at the biotech firm. At the same time, BioNTech reported an update on its mRNA cancer immunotherapy candidate BNT113 for HPV16-positive metastatic head and neck cancer, which commentators describe as the latest setback for the company's oncology programme.
Why now: A combination of workplace criticism and disappointing news on a key cancer drug candidate is drawing attention to BioNTech.
BioNTechBNT113n-tvT-OnlineGermany
Rank over time, top of the chart is #1. 6 snapshots from 25 d ago to 3 d ago.
Evidence
- "Toxische" Arbeitssituationen: Betriebsrat beklagt Missstände bei Biontech · n-tv.de
- Nächster Rückschlag für Biontech mit mRNA-Krebsimmuntherapie-Kandidaten · T-Online
- GNW-News: BioNTech veröffentlicht Update zur klinischen Phase-2/3-Studie des mRNA-Krebsimmuntherapiekandidaten BNT113 bei HPV16-positivem metastasiertem Kopf- und Halskrebs · boerse.de
API: https://socialmediatrends-api.osmike.com/v1/trends/2110055